tients treated so far with QbG10 in the different studies, we can see the following
picture: QbG10 seems to be active as a monotherapy; however, combination with an allergen extract
at a standard dose appears to enhance the therapeutic effect. The highest efficacy was achieved
when QbG10 was combined with a dose of allergen extract usually applied in conventional
desensitization therapy, i.e. a 10-times higher dose than the one tested in this present study. In a
next clinical trial we will test higher doses of CYT003-QbG10 monotherapy and compare the safety
and efficacy profile directly with the most promising product formulations of CYT005-AllQbG10 in
order to select the best product candidate for late stage development.”

CYT003-QbG10 Conference Call and Webcast
Cytos Biotechnology will host a conference call and Q&A session today, Tuesday, May 15, 2007 at
10 am (CET) to discuss the study findings.
To access the conference call, please dial the following numbers:
Europe +41 91 610 56 00
U.S. +1 866 291 41 66
U.K. +44 207 107 06 11

The conference call will be held in English and will also be accessible by webcast on the internet.
You may follow the call live or have it replayed later on demand. To access the webcast and the
presentation, please follow the link provided on our homepage www.cytos.com. The presentation
slides will be available for download 30 minutes prior to the conference call.

Among other projects, Cytos Biotechnology will also discuss its allergy program at the company’s
upcoming R&D day on Wednesday, June 20, 2007 at 2 pm (CET) at the company’s premises in
Schlieren.

About the phase IIa study and the analysis
The multi-centre, randomized, double-blind and placebo-controlled phase IIa study included 40 male'"/>




Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis